GFRAL Antisense Oligomers for Cachexia Pathway Inhibition

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is no effective therapeutic agent for suppressing the progression and facilitating recovery from cachexia, a severe condition characterized by muscle and adipose tissue loss, often caused by chronic diseases and cancer, which is not addressed by existing treatments such as appetite-stimulating drugs or anti-inflammatory drugs.

Innovation Solution

Development of a GFRAL-specific antisense oligomer that inhibits the expression of the GFRAL gene, targeting the GFRAL receptor activated by GDF15, to prevent or treat diseases associated with cachexia by neutralizing the effects of GDF15.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If GDF15 levels increase to activate GFRAL receptor, then appetite suppression and weight loss occur, but therapeutic intervention options are limited

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidtreatment options

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent introduces antisense oligomers as intermediary molecules that bind to GFRAL mRNA to prevent its translation into protein. This intermediary approach blocks the harmful GDF15-GFRAL signaling pathway without requiring direct modulation of GDF15 itself, thereby providing a novel therapeutic mechanism for cachexia treatment

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the molecular parameter of GFRAL expression levels by introducing antisense oligomers that specifically reduce GFRAL mRNA translation. This parameter change (from normal to suppressed GFRAL levels) directly interrupts the cachexia pathway and provides effective treatment where previous approaches failed

Inventive Principle:

Principle #35Parameter changes

2Ease of operation

If existing treatments like appetite-stimulating drugs or anti-inflammatory drugs are used, then general symptom management is achieved, but cachexia progression is not suppressed

Engineering Contradiction:

Improvetreatment accessibilityVSAvoidtherapeutic effectiveness

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent extracts and targets the specific molecular mechanism (GFRAL receptor signaling) that drives cachexia progression, separating it from general symptom management. By taking out the specific pathological pathway and targeting it with antisense oligomers, the invention achieves disease-modifying effects rather than merely managing symptoms

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention replaces the mechanical/pharmacological approach of general symptom management (appetite stimulation, anti-inflammatory drugs) with a molecular-level intervention (antisense oligomers) that directly addresses the underlying pathological mechanism of GDF15-GFRAL signaling

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If GFRAL expression is not inhibited, then the GDF15 signaling pathway remains active, but cachexia symptoms persist and quality of life decreases

Engineering Contradiction:

Improvedisease modificationVSAvoidcachexia symptoms

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary anti-action by using antisense oligomers to preemptively block GFRAL mRNA translation before the GDF15-GFRAL signaling pathway can be activated. This preliminary inhibition prevents the downstream harmful effects (appetite suppression, muscle wasting) before they occur

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

The invention converts the harmful overactive GDF15-GFRAL signaling pathway into a beneficial therapeutic target. By specifically targeting and suppressing GFRAL expression with antisense oligomers, the harmful cachexia-driven signaling is transformed into a controllable therapeutic mechanism that can be modulated to restore normal physiology

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The antisense oligomer effectively reduces GFRAL expression, thereby ameliorating cachexia symptoms by inhibiting the signaling pathway that leads to appetite suppression and weight loss, providing a potential therapeutic approach for cachexia.

Implementation Method 1

an oligomer capable of hybridizing with at least 13 consecutive nucleobases in an whole pre-mRNA of human GFRAL

Methodology Applied

Scientific EffectHybridization:

Implementation Method 2

through Watson-Crick base pairing A:T or G:C or wobble base pairing G:U, I:A, I:C or I:U

Methodology Applied

Scientific EffectWatson-Crick base pairing:

Implementation Method 3

GFRAL-specific antisense oligomer targeting the GFRAL (GDNF family receptor alpha like) gene

Methodology Applied

Scientific EffectAntisense oligonucleotide mechanism:

Data Source

PatentEP4653531A1Antisense oligomers targeting gfral and use thereof

Publication Date: 2025.11.26 THOR THERAPEUTICS INC

Figure 1~2a
Figure 2b~3b
Figure 4a~4b

AI summary

The present invention relates to: GFRAL-specific antisense oligomers targeting the GDNF family receptor alpha like (GFRAL) gene; and a pharmaceutical composition for preventing or treating obesity, diabetes, appetite loss, or cachexia, the pharmaceutical composition including the antisense oligomers. The antisense oligomers according to the present invention were found to effectively inhibit GFRAL expression in the body and exhibit amelioration effects in cancer cachexia animal models. Thus, the application of the antisense oligomers as an agent for treating obesity or cachexia through GFRAL expression inhibition is highly promising.